Hjem › Kronisk lymfatisk leukemi › Illinois › Chicago
Kliniske studier for Kronisk lymfatisk leukemi i Chicago, IL
14 studier for Kronisk lymfatisk leukemi søker deltakere på steder i og rundt Chicago (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
RekruttererFase 3
- Northwestern University, Chicago
- University of Illinois, Chicago
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
- Mount Sinai Hospital Medical Center, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- University of Illinois, Chicago
- og 1 flere
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
RekruttererFase 3
- Northwestern University, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
RekruttererFase 3
- Northwestern University, Chicago
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
RekruttererFase 3
- Northwestern University, Chicago
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
RekruttererFase 3
- University of Chicago Medical Center, Chicago
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
RekruttererFase 1
- The David and Etta Jonas Center for Cellular Therapy, Chicago
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
RekruttererFase 1
- Northwestern University, Chicago
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
RekruttererFase 1
- University of Chicago, Chicago
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
RekruttererFase 1/2
- University of Illinois at Chicago Cancer Center, Chicago
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
RekruttererFase 1
- The University of Chicago Medical Center, Chicago
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
RekruttererFase 4
- Northwestern University, Chicago
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
RekruttererFase 4
- Northwestern University, Chicago
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
RekruttererFase 1
- Northwestern Memorial Hospital, Chicago
Kronisk lymfatisk leukemi-studier i andre byer
- Boston, MA31 studier
- Columbus, OH28 studier
- Durham, NC27 studier
- Washington, DC22 studier
- Seattle, WA20 studier
- Rochester, MN19 studier
- New York City, NY18 studier
- Houston, TX17 studier
- Baldwin Park, CA16 studier
- Milwaukee, WI15 studier
- Cincinnati, OH14 studier
- Nashville, TN13 studier
Andre studier i Chicago
- Ikke-småcellet lungekreft61 studier
- Brystkreft58 studier
- Kreft (alle typer)51 studier
- Metastatisk kreft45 studier
- Prostatakreft45 studier
- Fedme41 studier
- Lungekreft41 studier
- Eggstokkreft36 studier
- Slag34 studier
- Kolorektal kreft33 studier
- Hjertesvikt31 studier
- Overvekt28 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.